Syringe Replacement Robotic Pills – $69 Million in Investment
For patients who require frequent use of syringes, such as diabetic patients, but are burdensome, the needle in the pill administers the drug without pain in the organ.
When the needle administers the drug, the transmitter inside the pill sends a signal to the device worn by the patient to check whether the drug is administered or not, and it can be shared with the doctor.
Rani Therapeutics
Rani Therapeutics develops an oral biotherapeutics technology for the oral delivery of large drug molecules, including peptides, proteins, and antibodies. The company was founded in 2012 and is based in San Jose, California.
General Information
- Headquarters : San Jose, CA
- Founders : Mir Imran
- Categories : Biotechnology, Pharmaceutical, Therapeutics
- Founded : 2012
- Contact : info@ranitherapeutics.com
Funding
- Funding Rounds (6) - $211.5M
- Dec 10, 2020 Series E / $69M
- Feb 7, 2018 Venture Round / $53M
- Sep 9, 2017 Series D / $39M
- May 26, 2015 Series C / $37.1M
- Jul 28, 2013 Series B / $9.4M
- Jun 13, 2012 Series A / $4M
1. Reason for attention
- Diabetic patients who need to self-administer their own insulin injections about 700 to 1000 times a year or multiple sclerosis who need to administer interferon beta 3 times a week
Injections are a very painful process for patients, and there is always a need for alternatives to injections.
- The cost of missing out on medication due to the high prices and the fear and pain of syringes is estimated to be in the hundreds of billions of dollars each year, accounting for more than 100,000 deaths and 10% of hospitalizations in the United States.
- RaniPill, developed by Rani Therapeutics, contains peptides, proteins, and antibody therapeutics, which reach the intestine and dissolve, and act by injecting the saliva containing the therapeutic agent into the intestine.
- This provides an innovative way for patients suffering from diseases such as diabetes, arthritis, psoriasis, and hemophilia that require constant injections to obtain the same effect without the effort and pain of injections by administering drugs orally instead of injections.
2. Product operation method
- RaniPill has a special coating that can withstand gastric acid and dissolves the coating in the intestine by pH changes from the stomach to the intestine.
- RaniPill, expanded by chemical reaction, dissolves and administers the drug by using pressure to insert the needle inside the pill into the intestinal wall. At this time, the barrier has no pain receptors, so the patient does not feel pain.
- Saliva made of sugar dissolves and other substances are excreted from the body, harmless to the human body.
- When the needle is inserted into the wall, a signal is sent out of the body by a wireless transmitter, and this signal is connected to a smartphone to check the exact administration time and then share it with the patient and the doctor
- In addition, a reminder function that notifies you when you have not taken your medication, so you can take your medication on a regular basis
3. Future Prospects
- Rani Therapeutics has not yet generated revenue from the product and is not expected to generate revenue for the next several years.
- Bio companies with no sales like Rani Therapeutics often raise funds by going public, but Rani Therapeutics has no plans to go public for the time being.
- If RaniPill is commercialized and oral antibody, peptide, and protein pills are developed, it is expected to completely change the current syringe-based therapeutics market.
Source: ranitherapeutics
👉• Web: http://www.ranitherapeutics.com
0 Comments